Who
James R. Gruber
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Eton Pharmaceuticals.
In numbers
- Trades disclosed
- 15
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $674K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 12 Jul 2022
- Last trade
- 14 Jan 2026
- Last filed
- 14 Jan 2026
Companies traded
Activity over time
1 Aug 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 Jan 2026filed 14 Jan 2026 | ETON Eton PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $35K2,293 at $15.47 | filing |
| 14 Jan 2026filed 14 Jan 2026 | ETON Eton PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $35K2,293 at $15.47 | filing |
| 12 Jan 2026filed 14 Jan 2026 | ETON Eton Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —40,655 at $0.00 | filing |
| 12 Jan 2026filed 14 Jan 2026 | ETON Eton Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —25,856 at $0.00 | filing |
| 12 Jan 2026filed 14 Jan 2026 | ETON Eton Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —40,655 at $0.00 | filing |
| 12 Jan 2026filed 14 Jan 2026 | ETON Eton Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —25,856 at $0.00 | filing |
| 12 Dec 2025filed 12 Dec 2025 | ETON Eton PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $77K4,542 at $16.99 | filing |
| 11 Dec 2025filed 12 Dec 2025 | ETON Eton Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —5,502 at $0.00 | filing |
| 20 Aug 2025filed 20 Aug 2025 | ETON Eton PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $42K2,631 at $16.02 | filing |
| 19 Aug 2025filed 20 Aug 2025 | ETON Eton PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $632K39,082 at $16.16 | filing |
| 3 Jan 2025filed 6 Jan 2025 | ETON Eton Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —38,621 at $0.00 | filing |
| 3 Jan 2025filed 6 Jan 2025 | ETON Eton Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —25,876 at $0.00 | filing |
| 13 Feb 2024filed 15 Feb 2024 | ETON Eton Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —144,677 at $0.00 | filing |
| 3 Mar 2023filed 3 Mar 2023 | ETON Eton Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —100,086 at $0.00 | filing |
| 12 Jul 2022filed 18 Jul 2022 | ETON Eton Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
News
Eton (NASDAQ: ETON) secures LIBERVANT license with milestones up to $47.5 millionETON · themarketsdaily.com · 14 Oct 2026Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal FilmETON · manilatimes.net · 14 Oct 2026Comparing Cronos Group (NASDAQ:CRON) and Eton Pharmaceuticals (NASDAQ:ETON)ETON · dailypolitical.com · 13 Oct 2026
0 headlines in the last 90 days name James R. Gruber; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.